生物制药公司Soleno Therapeutics近日宣布一项重要人事任命。根据2月25日提交至美国证券交易委员会（SEC）的文件显示，公司已正式任命Jennifer Fulk担任首席财务官（CFO）一职，该任命将于2026年3月2日正式生效。
此次高管变动标志着Soleno Therapeutics在战略布局上的重要一步。Jennifer Fulk在财务管理领域拥有丰富经验，预计将为公司带来新的发展动能。随着新任首席财务官的到位，Soleno Therapeutics有望进一步加强其财务运营体系，为未来业务拓展提供有力支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.